It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans

Daniel Higgins^{1,2‡*}, Joshua Looker^{1,2‡*}, Robert Sunnucks^{1,2‡*}, Jonathan Carruthers³, Thomas Finnie³, Matt J. Keeling^{2,4}, Edward M. Hill^{5,6*}

1 EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, United Kingdom.

2 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom.

3 Data, Analytics and Surveillance, UK Health Security Agency, Porton Down, United Kingdom. **4** Mathematics Institute and School of Life Sciences, University of Warwick, Coventry, United Kingdom.

5 Civic Health Innovation Labs and Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.

6 NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, United Kingdom.

‡These authors contributed equally to this work.

* Corresponding Authors. Emails: daniel.higgins@warwick.ac.uk; joshua.looker@warwick.ac.uk; rob.sunnucks@warwick.ac.uk; edward.hill@liverpool.ac.uk.

Abstract ¹

Avian influenza A(H5N1) poses a public health risk due to its pandemic potential should the virus 2 mutate to become human-to-human transmissible. To date, reported influenza $A(H5N1)$ human cases $\frac{3}{4}$ have typically occurred in the lower respiratory tract with a high case fatality rate. There is prior 4 evidence of some influenza A(H5N1) strains being a small number of amino acid mutations away from ⁵ achieving droplet transmissibility, possibly allowing them to be spread between humans. We present a mechanistic within-host influenza $A(H5N1)$ infection model, novel for its explicit consideration of the 7 biological differences between the upper and lower respiratory tracts. We then estimate a distribution $\frac{8}{100}$ of viral lifespans and effective replication rates in human H5N1 influenza cases. By combining our ⁹ within-host model with a viral mutation model, we determine the probability of an infected individual 10 generating a droplet transmissible strain of influenza $A(H5N1)$ through mutation. For three mutations, $_{11}$ we found a peak probability of approximately 10^{-3} that a human case of H5N1 influenza produces at 12 least one virion during the infectious period. Our findings provide insights into the risk of differing 13 infectious pathways of influenza A(H5N1) (namely avian-human vs avian-mammal-human routes), ¹⁴ demonstrating the three-mutation pathway being a cause of concern in human cases. ¹⁵

1 Introduction 16

The influenza virus family is responsible for influenza infections (colloquially referred to as the 'flu') $_{17}$ in a variety of animals including humans, other mammals and birds. There are four main influenza 18 types (A-D); within type A influenza there is substantial public health concern around the avian ¹⁹ influenza $A(H5N1)$ subtype, commonly known as bird flu. Influenza $A(H5N1)$, which we will refer 20 to as H5N1 influenza, is highly pathogenic in avian species and considered panzootic, being widely $_{21}$ distributton sipepvildepond newysstigated abind been certhibory player locane holuu novotted qogune tinuman iH5N1 22

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

influenza worldwide as of 23 May 2024 [\[2\]](#page-23-1). These reported cases have generally been severe, with a case 23 fatality rate of 53% [\[3\]](#page-23-2) although, at the time of writing, there is little evidence for human-to-human ²⁴ transmission of H5N1 [\[4\]](#page-23-3). Nonetheless, the high prevalence of the infection in the avian population is $_{25}$ causing mounting concerns that under the right circumstances, an H5N1 strain could mutate to allow ²⁶ human-to-human transmission. If this were to occur, transmission between humans is likely to allow 27 increased spread of the virus (at similar levels to the seasonal flu) with a resultant pandemic amongst ²⁸ humans.

Previous flu pandemics, and seasonal flu outbreaks, are primarily infections of the upper respiratory $\frac{30}{20}$ tract (URT) [\[5\]](#page-23-4) due to the presence of $SA_{\alpha}2,6$ receptors that these strains preferentially bind to α for cell entry. H5N1 influenza, however, preferentially binds to $SA_{\alpha}2,3$ receptors present in the avian 32 respiratory and intestinal tracts $[6–10]$ $[6–10]$, and these receptors are primarily found in the lower respiratory $\frac{33}{2}$ tract (LRT) in humans. This not only makes it much more difficult for initial human infection to occur, ³⁴ but also means that droplet transmission (the main source of seasonal flu transmission) is not viable, ³⁵ hence the current lack of human-to-human transmission of H5N1 influenza. However, with suitable 36 mutations within humans, H5N1 influenza could evolve the ability to infect the URT as well as the ³⁷ LRT. This is cause for concern for two reasons. Firstly, infections in the LRT may lead to greater 38 mortality due to increased risk of pneumonia and other related fatality risks [\[11\]](#page-24-1). Secondly, with the ³⁹ ability to infect the URT, human-to-human transmission becomes more likely, increasing the pandemic ⁴⁰ potential of H5N1 influenza $[6, 8, 9]$ $[6, 8, 9]$ $[6, 8, 9]$ $[6, 8, 9]$.

Prior studies found that five amino acid substitutions in H5N1 influenza were required for human-tohuman transmission to be possible at the time those experiments were conducted, with two of these $\frac{43}{43}$ mutations having already been seen in viruses sampled from the avian population [\[6\]](#page-23-5). It is believed ⁴⁴ that the other three mutations are unlikely to evolve in avian species as they are deleterious to the ⁴⁵ virus in birds. Consequently, between three and five mutations are likely required to take place in ⁴⁶ humans for droplet transmission to be likely. 47

For pandemic preparedness, it is crucial that we have suitable tools available to quantify the chance 48 of an infected individual generating a droplet transmissible strain of H5N1 influenza through muta- ⁴⁹ tion. However, the probability of such mutations in H5N1 influenza occurring within a human host is $\frac{50}{100}$ presently unknown. To enable modelling analysis of this problem, there are two key limitations in the ⁵¹ existing modelling literature. The first is that previous models of H5N1 influenza within-host infection 52 dynamics in humans do not take into account the differences between the two tracts (URT and LRT). $\frac{53}{100}$ Although there have been modelling efforts to account for the binding specificities of H5N1 influenza $_{54}$ in different areas of the respiratory tract $[7]$, and it is understood that fluid dynamic effects/having $\frac{55}{10}$ multiple patches impact contagion dynamics $[12-14]$ $[12-14]$, to our knowledge no current research explicitly $\frac{56}{12}$ models H5N1 influenza infection dynamics in the LRT and URT. The second is that although poten- ⁵⁷ tial mathematical frameworks for the modelling of advantageous mutations (such as those required 58 for droplet transmissibility) do exist in the literature, these have explored the implications of the 59 frameworks as opposed to explicitly finding the mutation probabilities $[6, 15, 16]$ $[6, 15, 16]$ $[6, 15, 16]$ $[6, 15, 16]$.

In this paper, we present a combined modelling framework to address these two notable methodolog- 61 ical gaps. The first modelling component is a novel within-host two-patch (both upper and lower ϵ_2 respiratory tract), ODE infection model for H5N1 influenza. By inferring patch-dependent disease 63 parameters, we seek to capture the biological differences in spreading capability of H5N1 influenza in ⁶⁴ the two parts of the respiratory tract. The second modelling component is an enhanced branching 65 process model (BPM) for H5N1 influenza virus mutation, building on the work of Russell *et al.* [\[6\]](#page-23-5). ⁶⁶ Informed by the within-host model outputs, and including the distribution of infection lifespans and σ real-time replication number estimates, we use the BPM to provide a more realistic estimate on the 68 evolutionary dynamics of a human H5N1 influenza infection. Combined, our modelling framework is ϵ_{9}

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

generalisable to other respiratory pathogens, allowing researchers to estimate the mutation chances ⁷⁰ for a pathogen mutating specific traits. The matrix of $\frac{1}{2}$ is the set of

2 Methods ⁷²

Herein we summarise the three main methodological components of our study. We begin with a description of the novel within-host deterministic infection model and its calibration to both the canonical 74 H5N1 influenza dataset and case fatality rate (Section [2.1\)](#page-2-0). This is followed by the introduction of τ the branching process model for viral mutation and how it incorporated the within-host model re- ⁷⁶ sults (Section [2.2\)](#page-9-0). Finally, we list the methods and model realisations used to calculate both the τ time dependent proportion of mutant virions in a host and the probability that a human-to-human τ transmissible strain could arise from an infection (Section [2.3\)](#page-10-0).

To simulate the within-host infection model (and its proxies) and the branching process model we so used Python 3.11 with packages: Numpy (version 1.26.4), Matplotlib (version 3.84), Scipy (version ϵ 1.13.0) and Pickle (version 4.0). We conducted the Approximate Bayesian Computation scheme for \approx fitting the within-host model in R 4.3 using the packages: tymtnorm (version 1.6), KS correct (version $\frac{1}{83}$ 1.4.0) and deSolve (version 1.40). A repository containing the data and code used to conduct this ⁸⁴ study can be found at <https://github.com/joshlooks/avianflu>. 85

2.1 Within-host infection model explanation and fitting the Second Second

Our within-host model for H5N1 influenza infection introduced key biological processes not present in $\frac{1}{87}$ other models in the literature. This model development subsequently forms the basis of the remaining ss results presented in this paper. Here we outline the canonical dataset used for fitting the intra-host 89 model (Section [2.1.1\)](#page-2-1), provide the biological description of the infection model (Section [2.1.2\)](#page-3-0) and ω state the corresponding ODE system (Section [2.1.3\)](#page-5-0). We then explain how the model parameters $\frac{91}{2}$ were calibrated using literature (Section [2.1.4\)](#page-5-1) and an Approximate Bayesian Computation scheme ₉₂ (Section [2.1.5\)](#page-6-0). Lastly, introducing mortality into our two-patch model was of utmost importance ⁹³ for informing how likely human-to-human transmission may be. The relatively high case fatality rate $\frac{94}{4}$ of H5N1 influenza could hamper its ability to mutate in the body since those infected may be likely ⁹⁵ to die before the virus has a chance to mutate to become human-to-human transmissible. We thus ⁹⁶ conclude this section by outlining how we fit the model outputs to mortality data (Section [2.1.6\)](#page-7-0). $\qquad \qquad$ 97

2.1.1 Data 98

We made use of the ubiquitous dataset in the literature corresponding to the viral titres of eighteen ⁹⁹ hospitalised H5N1 influenza patients in Vietnam in 2004 and 2005 [\[17\]](#page-24-6). As the raw data were not 100 publicly available, we estimated the viral titre values from Supplementary Figure 1 in de Jong *et al.* ¹⁰¹ [\[17\]](#page-24-6); given the large variation in the data point values we expect our estimation procedure to have ¹⁰² little effect on the takeaways presented. The titrations were formed from pharyngeal swabs taken 103 after presentation at the hospital. These measurements corresponded to the viral load in the URT ¹⁰⁴ only, with viral loads varying in many orders of magnitude between patients on the same estimated ¹⁰⁵ day post-infection (Fig. [1\)](#page-3-1). We anticipated that this characteristic of the data, and the small, noisy ¹⁰⁶ sample, could pose issues around parameter identifiability and model generalisation to an 'average 107 infection' during model fitting. Nonetheless, this dataset is the most recent and complete human 108 infection data available for H5N1 influenza. Prior studies attempting to calibrate models to these ¹⁰⁹ data have gathered an understanding of related biological processes [\[7,](#page-23-8) [18\]](#page-24-7). It thereby provides an $_{110}$ entry point for calibration of our proposed model and the exploration of its infection dynamics.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Fig. 1. Viral titres from pharyngeal swabs of hospitalised H5N1 influenza patients in Vietnam. Data from de Jong *et al.* [\[17\]](#page-24-6), where viral RNA loads were measured in throat swabs obtained at admission from 18 H5N1 patients. We used this dataset to calibrate all models included in this paper.

2.1.2 Deterministic two-patch infection model description 112

We first built a deterministic two-patch ordinary differential equation infection model, with the URT 113 and LRT each having their own internal processes. The URT and LRT then interact via the diffusion $_{114}$ of the free virus between each patch and an advection term, describing the movement of free virus ¹¹⁵ between patches via physical movement of fluid. The advection term can be considered the transfer ¹¹⁶ of mucus (through coughing or mucociliary clearance by cilia) from the LRT to the URT. A graphical ¹¹⁷ depiction of the above processes is shown in Fig. [2.](#page-4-0) 118

For the within-patch processes (the cells subfigure in Fig. [2\)](#page-4-0), we modelled each respiratory tract $_{119}$ compartment as having a set of uninfected epithelial cells (or 'target cells', T) to which the H5N1 $_{120}$ influenza virions (V) may bind. After infection by a virion, the cells move into an eclipse/latent 121 phase (E) where they are infected by the virus but do not produce any additional virions. After an $_{122}$ exponentially-distributed period of time, the cells leave the latent phase and enter the infected phase ¹²³ (I) , producing free virions. LRT models for Influenza A have been studied previously; we based our $_{124}$ more complex two-patch model on a model of the infection in the LRT by Handel *et al.* [\[19\]](#page-24-8). We note ¹²⁵ in particular that the key difference between the URT patch and the LRT patch is that it is generally ¹²⁶ considered that the URT can be modelled using a 'target-cell limited' approach. In other words, there ¹²⁷ is limited immune response in the URT and the dynamics of the virus are entirely governed by the ¹²⁸ number of uninfected cells alive. Thus, we only considered an immune response in the LRT patch. ¹²⁹ The adaptive immune response (X) has a humoral component comprised of B-cells and antibodies, as $_{130}$ well as a cellular component, comprised of T-cells. The humoral component causes the IR to increase 131 proportionally to the viral load in the LRT, and the clonal expansion of the T-cells causes the IR to ¹³² grow exponentially, as in Handel *et al.* [\[19\]](#page-24-8). X can be considered to represent antibodies in the host. ¹³³

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.01.24312235;](https://doi.org/10.1101/2024.09.01.24312235) this version posted December 20, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Fig. 2. LRT and URT explicit within-host respiratory infection model schematic.

Compartments listed are uninfected/target cells (T) , free virions (V) , eclipse/latent cells (E) , infected/virion-producing cells (I) and the adaptive immune response (X) . Note that the subscripts U, L represent the URT- and LRT-based compartments respectively. The different colours represent the processes in the URT (in blue) and in the LRT (red). Arrows show the spread of the contagion through the host. The dashed arrows in the virus compartment indicate the coupling of the two patches through advection and diffusion. Parameters descriptions are found in Table [1.](#page-7-1)

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

2.1.3 ODE system 134

The within-host dynamics of H5N1 infection obeyed the following system of ordinary differential equa- ¹³⁵ tions. We note that a subscript U denotes that the compartment / parameter is for the URT, while $\frac{1}{36}$ a subscript L denotes that the compartment / parameter is for the LRT.

$$
\frac{dT_U}{dt} = -\beta_U T_U V_U
$$
\n
$$
\frac{dE_U}{dt} = \beta_U T_U V_U - gE_U
$$
\n
$$
\frac{dI_U}{dt} = gE_U - dI_U
$$
\n
$$
\frac{dV_U}{dt} = p_U I_U - cV_U - \gamma \beta_U T_U V_U - D(V_U - V_L) + aV_L
$$
\n
$$
\frac{dT_L}{dt} = -\beta_L T_L V_L
$$
\n
$$
\frac{dE_L}{dt} = \beta_L T_L V_L - gE_L
$$
\n
$$
\frac{dI_L}{dt} = gE_L - dI_L
$$
\n
$$
\frac{dV_L}{dt} = p_L I_L - cV_L - \gamma \beta_L T_L V_L - kV_L X + D(V_U - V_L) - aV_L
$$
\n
$$
\frac{dX}{dt} = fV_L + rX
$$

with β_U and β_L the rate of infection in the URT and LRT, g the latent transition rate of infected cells, 139 d the mortality rate of infected virus producing cells , p_U and p_L the virus production rate in the URT 140 and LRT, c the morality rate of free virions, γ the conversion rate between infection and viral titre, f μ_1 the recruitment rate of adaptive immune response, r the expansion rate of adaptive immune response $\frac{142}{2}$ and k the kill rate of adaptive immune response, D the rate of diffusion and a the rate of advection. $\frac{143}{2}$

2.1.4 Model parameterisation from the literature 144

We obtained values from the literature for a subset of parameters in our ODE model. From Dobrovolny 145 *et al.* [\[18\]](#page-24-7), we set the latent state duration of infected cells $(1/g)$ as $1/4$ days, the lifespan of infected 146 virus producing cells $(1/d)$ to be $1/5.2$ days and the lifespan of free virions $(1/c)$ as $1/2$ day. We also $1/47$ highlight that Dobrovolny *et al.* [\[18\]](#page-24-7) noted that their values were consistent with other research in the 148 area. ¹⁴⁹

For the immune parameters, we took the approach found in Handel *et al.* [\[19\]](#page-24-8). Although this was 150 fitted to mice data, studies have shown that the mice immune system is a suitable analogue for the ¹⁵¹ immune system found in humans *in vivo* [\[20\]](#page-24-9). Further, parameters are likely transferable through ¹⁵² the comparison of mice and human metabolic rates - mice have a metabolic rate seven times that of ¹⁵³ humans [\[21\]](#page-24-10). We converted from plaque-forming unit (pfu) into $TCID_{50}$ (Tissue culture infectious 154 dose 50%), with pfu being proportional to TCID50 by a factor of 0.56 [\[22\]](#page-24-11).

It was also important to select an initial number of target cells and initial viral load. We took the ¹⁵⁶ estimated values of $T_U = 4 \times 10^8$, $T_L = 6.25 \times 10^9$ from Ciupe and Tuncer [\[23\]](#page-24-12), which were calculated 157

138

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

using the average surface area of an epithelial cell and of the human respiratory tract. We took the ¹⁵⁸ initial viral load $(V_0 = 1.3 \times 10^3 \text{ TCID}_{50}/\text{ml})$ from the fitted values of the single-target-cell model in 159 Dobrovolny *et al.* [\[7\]](#page-23-8).

There was little information in the literature regarding rate of infection β_U and β_L , virus production 161 rate p_U and p_L , conversion rate between infection and viral titre γ , rate of diffusion D or rate of 162 advection a. These parameters of interest were also chosen as they have been found to have the ¹⁶³ biggest impact on the observed disease dynamics [\[7,](#page-23-8) [14,](#page-24-3) [18\]](#page-24-7). It is also worth noting that setting ¹⁶⁴ $\gamma = 0$ leads to similar results (and is normally ignored in human models [\[14,](#page-24-3) [18,](#page-24-7) [19\]](#page-24-8)). This parameter 165 represents the conversion rate between the viral titre (in $TCID_{50}$) and the number of free virions used 166 to infect a target-cell. Setting this parameter to zero indicates that there is no noticeable change in ¹⁶⁷ the viral titre due to the infection of target-cells. By re-introducing this parameter (allowing it to ¹⁶⁸ be non-zero), we gained an extra degree of freedom in the model that allowed for more biologically ¹⁶⁹ realistic parameter values and peak shapes to be observed during parameter fitting.

We state the default model parameters, for non-fitted parameters, in Table [1.](#page-7-1) Some of the selected $_{171}$ parameter values are similar to literature values for models fitted to H1N1 infection data within ¹⁷² humans [\[24](#page-24-13)[–26\]](#page-24-14). However, previous studies on H5N1 influenza infection in humans found that these 173 values gave good fits to the data, and that the other aforementioned parameters that we fitted for ¹⁷⁴ were the main contributors to viral dynamics [\[7,](#page-23-8) [18\]](#page-24-7).

2.1.5 Model calibration and parameter inference 176

To calibrate the model, we made use of the dataset outlined in Section [2.1.1.](#page-2-1) We note that these data ¹⁷⁷ correspond to the viral load in the URT only, meaning we could only fit the model dynamics based on ¹⁷⁸ the URT compartments. Parameter identifiability is a problem for most mathematical biology models, ¹⁷⁹ and this was especially true for our fitting process as we had less than 20 data points available, all of ¹⁸⁰ which corresponded to hospitalised individuals who died from the infection.

To fit the parameters we employed an Approximate Bayesian Computation Sequential Monte Carlo ¹⁸² *M* Nearest Neighbours (ABC-SMC-MNN) method based on the pseudo-code found in Minter and 183 Retkute [\[27\]](#page-25-0), using methods originally developed by Filippi *et al.* [\[28\]](#page-25-1) and Toni *et al.* [\[29\]](#page-25-2). Due to ¹⁸⁴ the lack of data, and its continuous nature, an exact likelihood function for data fitting is difficult to ¹⁸⁵ justify, thus we adopted an ABC inference scheme. With large order of magnitude differences across ¹⁸⁶ our data points, we chose the summary statistic (c) to be the model error on a log-scale, where y is 187 the data, N is the number of data points and x is the model predictions:

$$
c = \sum_{i=1}^{N} (\log (y_i) - \log (x_i))^2
$$

We chose the perturbation kernel to be a truncated-multivariate-normal distribution (truncated to take into account the prior). For the prior distributions, we assumed log-uniform prior distribution ¹⁹⁰ for all variables (see Table [1](#page-7-1) for the prior distribution ranges). We selected log-uniform priors as it is ¹⁹¹ an uninformative prior and because the parameters were likely to be skewed towards lower orders of ¹⁹² magnitude (such that our prior belief was the parameters being uniform on a log-scale). We informed ¹⁹³ the parameter ranges of the priors by first taking a least-squares fit (to both the normal and log-scale ¹⁹⁴ data); we then took a wide range around those values to define the prior bounds. Furthermore, we 195 also assumed the spreading rate in the LRT (β_L) to be greater than that in the URT (β_U) . This 196 is because H5N1 influenza preferentially binds to proteins more commonly found in the LRT as the ¹⁹⁷ type of receptor expression in the LRT is more similar to the avian respiratory tract [\[7,](#page-23-8) [30](#page-25-3)[–32\]](#page-25-4). The ¹⁹⁸

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Table 1. List of model parameters and their descriptions. For fixed parameters we state their value and associated references. For inferred parameters we list their prior distribution (we use lU as a notation for the log-uniform distribution). We provide unit information for each parameter in parenthesis after the parameter description.

Parameter		Value	Prior
β_U	URT Rate of infection, (day^{-1})		$lU(1\times10^{-8}, 1\times10^{-6})$
β_L	Rate of infection, LRT (day^{-1})	\equiv	$lU(1\times10^{-7}, 1\times10^{-5})$
1/g	Productively infected cells (days)	$1/4$ [18]	$\overline{}$
1/d	Lifespan of infected, virus- producing cells (days)	$1/5.2$ [18]	$\overline{}$
p_U	Virus production rate, URT (day^{-1})		$\overline{lU(1\times 10^{-4},1)}$
p_L	Virus production rate, LRT (day^{-1})	\equiv	$lU(1\times 10^{-4},1)$
1/c	Lifespan of free virions (days)	$1/2$ [18]	
γ	Conversion between infec-		$lU(1\times10^{-6}, 2\times10^{-3})$
	tious virions and $TCID_{50}$ /		
	PFU (unitless)		
\boldsymbol{f}	Recruitment rate of adaptive	$0.56 \times 2.8 \times 10^{-6} / 7$ [19] (fig	$\overline{}$
	immune response (day^{-1})	6)	
\mathcal{r}	Expansion rate of adaptive	$0.27/7$ [19] (fig 6)	$\overline{}$
	immune response (day^{-1})		
\boldsymbol{k}	Kill rate of adaptive immune	20 [19]	\equiv
	response (day^{-1})		
\boldsymbol{D}	Rate of diffusion of free viri-	\equiv	$\overline{lU(1\times 10^{-3},1)}$
	ons (day^{-1})		
\boldsymbol{a}	Rate of advection (day^{-1})	$\overline{}$	$lU(1\times 10^{-3}, 1)$

chosen hyper-parameters for the algorithm were to run the method adaptively, with an error tolerance ¹⁹⁹ in the first generation of 180. The error tolerance for subsequent generations was then set at the 40^{th} 200 percentile of the previous generations' particles. We set the algorithm to terminate either after 10 ²⁰¹ generations, or when the error tolerance changed by less than 1% between subsequent generations. 202 We ran the algorithm for the full ten generations, with a final (adaptive) error threshold of 141.58 203 (compared to a 142.1 tolerance in the previous generation). The error threshold in the final generation ²⁰⁴ had similar error to the least-squares fit value of 120.9.

2.1.6 Mortality 206

It is currently believed that a leading cause of death amongst H5N1 influenza patients is a phenomenon ²⁰⁷ known as a 'cytokine storm' [\[33\]](#page-25-5). This occurs when the immune response to the virus is elevated to ²⁰⁸ the point where the body overwhelms itself, causing massive inflammation and ultimately death [\[34\]](#page-25-6). ²⁰⁹

Since a cytokine storm results from the immune system's sustained response to viral load, for our ²¹⁰ two-patch model we took cumulative viral load as a proxy for mortality. In particular, we considered ²¹¹

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

the integral of the logarithm of the viral load over time as our metric for mortality: 212

$$
\int_0^t \log (V_U(s) + V_L(s)) ds > M
$$

with M a constant. To determine the value of M, we took the case fatality rate of 53% given in Sah $_{213}$ *et al.* [\[3\]](#page-23-2) and found the value of M that corresponded to said case fatality rate from the results of our ²¹⁴ stochastic simulations. In doing so, we set $M = 162.280$.

We also conducted a sensitivity analysis of our results to a lower case fatality rate of 20%. This value 216 was taken from Dobrovolny *et al.* [\[18\]](#page-24-7) for individuals treated with neuraminidase inhibitors and lead 217 to a higher M value of 177.328.

Introducing the proxy for mortality given above, we calculated the total length of infection for each ²¹⁹ of our infection simulations. We considered the infection to be finished when either a patient dies or ²²⁰ their total viral load fell below $V_U + V_L < 10^4$, i.e. , i.e. 221

$$
T = \sup_{t} \{ t \in \mathbb{R}^+ : \mathbb{1}_{\{\text{patient alive}\}}(t) [V_U(t) + V_L(t)] > 10^4 \}
$$

From this, we calculated an empirical distribution for T that we used to model viral mutations within $_{222}$ humans (Fig. [3\(a\)\)](#page-8-0). When taking a case fatality rate of 53%, most of the empirical distribution $_{223}$ for T occurred between eleven to thirteen days post infection, having reasonable correspondence to $_{224}$ previously recorded infections of (and modelling efforts for) H5N1 influenza infections lasting for ²²⁵ around ten days [\[6,](#page-23-5) [7,](#page-23-8) [18\]](#page-24-7). When instead assuming a case fatality rate of 20%, most of the empirical ²²⁶ distribution for T was between twelve and fifteen days (Fig. [3\(b\)\)](#page-8-0).

Fig. 3. Viral lifespan (T**) distributions under each case fatality rate assumption.** The assumed case fatality rates were **(a)** 53% and **(b)** 20%, respectively. We obtained the viral lifespan distributions by determining when either the viral load dropped below 10^4 or the integral under the log curve reached a value M . We performed the fitting method outlined in Section [2.1.6.](#page-7-0)

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

2.2 Mutation modelling and viral dynamics ²²⁸

From outputs that could be generated from our two-patch within-host model, we next needed an $_{229}$ additional modelling component that would enable us to calculate the proportion of virions with ²³⁰ zero, one, two, three, four and five mutations, and the probability that any given virion within the ²³¹ body had this number of mutations. In this section we outline our adapted stochastic branching 232 process mutation model used for this purpose. This model contains biologically informed values for ²³³ key model parameters, informed by the incorporation of results from the within-host infection model, ²³⁴ thus providing a prominent modelling advance.

We adapted the stochastic branching process mutation model for viral mutation introduced in Russell 236 *et al.* [\[6\]](#page-23-5), in which viral replication occurs at fixed time intervals of length Δ with a mutation rate 237 μ and replication rate r. The total number of viruses with j mutations at each time step $t_k = k\Delta$ 238 (with $k \in \mathbb{N}$ and $t_k < T$), $N_{t_k}^{(j)}$ $t_k^{(0)}$, is then given as a Poisson random variable: 239

$$
N_{t_k}^{(j)} \sim \text{Poi}(r \sum_{i=0}^{5} N_{t_{k-1}}^{(i)} \mu_{ij})
$$

where 240

$$
\mu_{ij} = \mathbb{P}(\text{Mutates from } i \text{ to } j \text{ mutations}) = \begin{cases} \mu^{j-i} & \text{for } i < j \\ 1 - 1_{\{i < 5\}} \sum_{j=i+1}^5 \mu^{j-i} & \text{for } i = j \\ 0 & \text{otherwise} \end{cases}
$$

Note that the rate of $N_{t_k}^{(j)}$ $t_k^{(J)}$ is a summation due to the additive property of the Poisson random variable. 241

We adapted the above process to allow for model parameters to be informed from the fitted within- 242 host infection model. We allowed r to be a function of time, $r(t_k)$, rather than a fixed value. Our 243 branching process was thus instead defined by: ²⁴⁴

$$
N_{t_k}^{(j)} \sim \text{Poi}(r(t_k) \sum_{i=0}^{5} N_{t_{k-1}}^{(i)} \mu_{ij})
$$

The function $r(t_k)$ represents the viral replication rate as derived from our two-patch within-host 245 model. To define it, we first express a partition P of $[t_k, t_{k+1}]$ such that $t_k = \tau_0 < \tau_1 < \cdots < \tau_m = t_{k+1}$ 246 with $\tau_{i+1} - \tau_i = \delta$ where δ is the rate at which the ODE system is updated when solved numerically. 247 It is then given by the product of the weighted sum of the number of virions created and destroyed ²⁴⁸ at each time step δ in each tract: 249

$$
r(t_k) = \prod_{l=1}^{m} \frac{\sum_{S \in \{U, L\}} R_{\tau_l}^{(S)} K_{\tau_l}^{(S)} V_{\tau_{l-1}}^{(S)}}{V_{\tau_l}}
$$

which is dependent on these four functions (with $S \in \{U, L\}$, denoting whether the value corresponds 250 to the URT or LRT and $N, V, D, p, I, c, V, \beta, T, k, X$ and V are as described in Section [2.1.3\)](#page-5-0):

The growth rate of new virions
$$
R_{\tau_l}^{(S)} = 1 + \frac{N_{\tau_l}^{(S)} - N_{\tau_{l-1}}^{(S)}}{V_{\tau_{l-1}}},
$$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

 \sqrt{S}

The death rate of existing virions

$$
K_{\tau_l}^{(S)} = 1 - \frac{D_{\tau_l}^{(S)} - D_{\tau_{l-1}}^{(S)}}{V_{\tau_{l-1}}},\tag{254}
$$

The rate of virion production
$$
\frac{dN^{(S)}}{dt} = p^{(S)}I^{(S)},
$$

$$
\frac{dN^{(S)}}{dt} = p^{(S)}I^{(S)},
$$

The rate of virion removal
$$
\frac{dD^{(S)}}{dt} = cV^{(S)} + \beta^{(S)}T^{(S)}V^{(S)} + 1_{\{S=L\}}kXV^{(S)}.
$$

2.3 Mutant virion proportions and probabilities ²⁵⁸

Our final piece of analysis involved exploring the time dependent proportion of mutant virions in a ²⁵⁹ host and the probability that a human-to-human transmissible strain could arise from an infection. 260 Previous studies have found that up to two of the required five H5N1 influenza mutations can naturally $_{261}$ occur in birds [\[6\]](#page-23-5). Depending on the number of mutations that have occurred prior to the human ²⁶² H5N1 influenza case, mutant virions then require either three out of three, four out of four, or five out ²⁶³ of five of the required mutations for droplet transmission. Results from the branching process model ²⁶⁴ allowed us to inform the probability that at any given time during the infection, the human host has at ²⁶⁵ least one virion with the necessary number of mutations required for human-to-human transmission. ²⁶⁶ Note that we term "X out of X mutations" for instances where the required total five mutations to $_{267}$ achieve droplet transmission could be obtained during the infection episode of the human case (i.e. ²⁶⁸ acquiring three or more mutations during the human infection case episode). ²⁶⁹

We ran the branching process model for viral mutation over the 1000 posterior predictive trajectories 270 acquired via the procedure outlined in Section [2.1.5.](#page-6-0) We initialised the starting viral load as 10^6 271 virions in each realisation. Our reasoning for that choice is as follows. The initial viral count in our 272 two-patch within-host model was 1.3×10^3 TCID₅₀/ml. For influenza A virions, the viral count per ml 273 is around four orders of magnitude greater than the $TCID_{50}/ml$ value [\[35\]](#page-25-7). Using these two pieces of $_{274}$ information, this gave us a viral density of approximately 10^7 virions per ml. Then, taking an initial 275 infected droplet of size 10^{-1} ml, we arrive at an initial viral count of 10^6 virions. In these simulations 276 we also took Δ (the period between replications) to be six hours, noting that δ (the update rate of 277 the two-patch within-host model solutions) is 0.001 days. This corresponds to the virions making two ²⁷⁸ replication cycles (one from cRNA to vRNA and then back to cRNA) every 0.5 days, as in Russell ²⁷⁹ $et \ al. \ [6].$ $et \ al. \ [6].$ $et \ al. \ [6].$

We ran two sets of simulations of the branching process model. The first was a set of one million BPM $_{281}$ realisations (1000 copies of each of the 1000 sets of parameter samples in the posterior distribution), 282 seeding the infection with an initial viral load of 10^6 virions.

The second was a set of 1000 BPM realisations (one for each of the parameter sample sets in the ²⁸⁴ parameter posterior distribution) with $10^6 \times 10^6$ initial virions (to simulate one billion people, but 285 combining BPMs to save on computation time). This provided a higher precision in the calculation ²⁸⁶ of mutation virus proportions.

We also calculated the probability that an individual had at least one virion exhibiting a specific 288 number of mutations. This provided another indication of the likelihood of an infection mutating to ²⁸⁹ allow for human-to-human droplet transmission. This probability calculation was, however, intractable ²⁹⁰ for the BPM that simulated one billion people as it required being able to differentiate between ²⁹¹ individuals (not possible here as we combined BPMs as it is computationally expensive to run the ²⁹² number of individual realisations needed to achieve the required level of precision). We thus introduced 293

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

an upper-bound estimate for this probability at time t. Using this approximation allowed for a $_{294}$ probability approximation to be produced for a much higher number of BPM realisations. ²⁹⁵

The approximation was as follows. Let V_t be the (mean) virion count for an individual at time t , 296 and $V_t^{(i)}$ be the (mean) number of virions with i mutations for an individual at time t. Additionally, 297 given an (average) infected individual, let A be the event that this individual has no virions with i_{298} mutations at time t and B_k be the event that virion k in this individual does not have i mutations at 299 time t, where $k = 1, 2, ..., V_t$. Then, . Then, 300

 $P(\text{An individual at time } t \text{ has at least one virion which has undergone } i \text{ mutations})$ 301

$$
= 1 - \mathbb{P}(A)
$$

= 1 - \mathbb{P}(\bigcap_{k=1}^{V_t} B_k)
= 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k \mid \bigcap_{i < k} B_i) (B_k - B_k)

$$
= 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k \mid \bigcap_{j < k} B_j) \\
\leq 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k) \\
\leq 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k) \\
\leq \prod_{k=1}^{V_t} \mathbb{
$$

$$
= 1 - \prod_{k=1}^{V_t} (1 - \frac{V_t^{(i)}}{V_t})
$$

= 1 - (1 - \frac{V_t^{(i)}}{V_t})^{V_t} = \hat{p}_t^{(i)}, i = 0, 1, 2, 3, 4, 5

To justify the inequality, we first note that if an arbitrary virion at the current timestep has i mutations, $\frac{309}{200}$ the probability that any other virion has that number of mutations would increase. This is because ³¹⁰ there is a chance that virions with the same number of mutations could have the same parent. The ³¹¹ joint probability events $(B_k | \bigcap_{j < k} B_j)$ takes into account this positive correlation (but the event B_k siz by itself does not), i.e. $\mathbb{P}(B_k \mid \bigcap_{j < k}^{\infty} B_j) \geq \mathbb{P}(B_k)$ 313

Additionally, since each virion is equally likely to mutate, we used the proportion of virions with i_{314} mutations to get that $\mathbb{P}(B_k) = 1 - \frac{V_t^{(i)}}{V}$ t V_t $\forall k$. 315

308

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

3 Results ³¹⁶

3.1 Fitting the two-tract within-host respiratory infection model to H5N1 in- ³¹⁷ **fluenza viral titre data** 318

Having developed our within-host respiratory infection model, with infection dynamics in the LRT ³¹⁹ and URT modelled explicitly, it was important to ascertain whether it could reproduce the observed $\frac{320}{200}$ H5N1 influenza viral titres (Fig. [1\)](#page-3-1) whilst maintaining biologically reasonable parameters. Resultant 321 parameter posteriors would then be used as inputs to the branching process model. ³²²

We ran the ABC-SMC-MNN routine and obtained 1000 samples of the posterior distribution for seven 323 fitted parameters: β_U , β_L , p_U , p_L , γ , D and a (Fig. [4\)](#page-13-0). We note that even for the posteriors that α_2 had similarities to a log-uniform distribution $(\beta_L, p_L, \gamma, D, a)$, the range and probability mass of these 325 distributions shifted compared to the prior. This is reinforced by a least-squares fit producing a ³²⁶ similar profile to the median of the posterior-predictive distribution (Fig. $5(a)$). The least-squares fit 327 parameters can be found in Section [S1.](#page-28-0) 328

Comparing the inferred posterior distributions for the URT and LRT spreading rate parameters, the ³²⁹ 95% credible interval for the spreading rate in the URT $(\beta_U \in [2.24 \times 10^{-7}, 3.47 \times 10^{-7}])$ was generally 330 at a lower range than in the LRT $(\beta_L \in [1.09 \times 10^{-7}, 1.18 \times 10^{-6}])$. This difference possibly corresponds 331 to the preferential binding of H5N1 influenza to the epithelial cells in the LRT than in the URT. The 332 production rate in the URT ($p_U \in [0.348, 0.608]$) was higher than in the LRT ($p_L \in [0.00488, 0.044]$), 333 likely due to the higher target-cell count (and thus maximum production rate) in the LRT. There 334 was a clear negative correlation between β_U and p_U (relating to the previous discussion), which is to 335 be expected as an increase in the spreading rate would lead to target-cells being infected sooner and ³³⁶ hence a larger infection time available to produce virions (meaning that a lower p_U is required) and 337 vice-versa. The 95% credible interval for γ was at a low range of $[2.72 \times 10^{-6}, 2.97 \times 10^{-4}]$, indicating 338 that the parameter was needed to delay the peak time, but only at smaller values. The 95% credible ³³⁹ intervals for the diffusion $(D \in [0.00141, 0.0680])$ and advection $(a \in [0.0414, 0.731])$ coefficients are 340 quite wide, possibly indicating that the intra-patch processes contribute more than the inter-patch $\frac{341}{2}$ processes to the viral dynamics. $\frac{342}{2}$

Through simulation of our model using the 1000 parameter sets representing samples from the target 343 posterior distribution, we next checked the correspondence between the posterior predictive distribu- ³⁴⁴ tion for V_U and the empirical viral titre data (Fig. [5\(a\)\)](#page-15-0). As the data is wide ranging - the smallest 345 viral titre measured had a value of around $10^4 T CID_{50}/ml$ with the highest being at over 10^8 - the 346 likelihood surface has many steep local minima giving a tight posterior interval. However, it can also $\frac{347}{40}$ be seen that the least squares solution (Section [S1\)](#page-28-0) lies close to the median produced by the ABC ³⁴⁸ method, giving confidence about the validity of the solution. The predictive interval lay within the ³⁴⁹ middle range of the dataset. The qualitative shape (including peak height and time) of the median was $\frac{350}{2}$ very similar to other models [\[7,](#page-23-8) [14,](#page-24-3) [18,](#page-24-7) [36\]](#page-25-8). For the least-squares optimisation we chose five different ³⁵¹ starting parameter sets and selected the resultant local mode with the lower error. Although not ³⁵² guaranteed, we are confident that this is likely the global optima as multiple starting points converged ³⁵³ to this value. This outcome supports the parameter posterior distributions acquired by the ABC ³⁵⁴ approach successfully incorporating the posterior. $\frac{355}{255}$

Lastly, inspection of the peak time distribution of viral titre realisations from the posterior predictive $\frac{356}{2}$ distribution showed almost all of the density of peak viral titre occurring between 4.7 and 5 days post $\frac{357}{20}$ infection (Fig. $5(c)$). This observation provided further assurance in the concordance between the 358 fitted model and the empirical data. $\frac{359}{256}$

Fig. 4. Parameter posterior distributions. We obtained 1000 samples of the target posterior distribution using the ABC-SMC-MNN method outlined in Section [2.1.5.](#page-6-0) Diagonal panels show the marginal distributions for: rate of infection in the URT (β_U) and the LRT (β_L) , virus reproduction rate in the URT (p_U) and the LRT (p_L) , conversion rate between infection and viral titre (γ) , rate of diffusion of free virions (D) and the rate of advection (a) , respectively. Off-diagonal panels show bi-parameter distributions, where the contour shading intensity corresponds to the probability density value (lighter for higher probability density). Parameters (β_L, p_L) in the LRT tended to be higher than the URT (β_U, p_U) , agreeing with the biological preference for H5N1 influenza to infect the LRT.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

3.2 Viral dynamics and branching factor by survival status 360

Having acquired posterior predictive trajectories for the viral load, we fit the resultant values using ³⁶¹ the mortality proxy (Section [2.1.6\)](#page-7-0). This process allowed for the separation of simulated stochastic ³⁶² viral dynamics into individual who cleared the infection and those who died $(Fig. 6(a))$ $(Fig. 6(a))$.

Noting that the virion count is proportional to the viral titre (and so should follow the same dynamics), ³⁶⁴ we can see that the median shape of the BPM is similar to the median of the within-host ODE model $\frac{1}{365}$ (comparing Fig. $6(a)$ to Fig. $5(a)$). However, we do see a secondary peak in the viral count in many of 366 the infections. These correspond to a delayed, and high, peak in the lower respiratory tract. We also $\frac{367}{267}$ see that individuals with this second peak are those who survived infection. Indeed, while this second 368 peak is higher, the infection dies off much earlier, and so these individuals have a lower sustained viral ³⁶⁹ load (and thus the area under the curve in the mortality proxy, is lower). 370

For the posterior distribution of replication rates $(r(t))$ trajectories, in the majority of realisations $\frac{371}{271}$ $r(t)$ between days zero and four was essentially constant (Fig. [6\(b\)\)](#page-16-0), corresponding to the exponential 372 growth of v (Fig. $6(a)$). All of the trajectories also display a second increase in replication rates around 373 day seven. In particular, individuals who died as a result of infection saw a slightly delayed and higher 374 second peak in $r(t)$, corresponding to the more sustained viral load exhibited (Fig. [6\(a\)\)](#page-16-0). Studying 375 the relationship between viral lifespan and peak replication rate $(r(t))$, there was minimal correlation $\frac{376}{2}$ between the two variables (Fig. $6(c)$). 377

When instead considering a case fatality rate of 20% , with individuals on average surviving longer $\frac{378}{200}$ given a lower case fatality rate, the range of viral lifespan was slightly shifted; those who died generally ³⁷⁹ had a lifespan between 11.5 and 14 days (Fig. [3\(b\)\)](#page-8-0). This contrasted to the viral lifespan distribution obtained in our main analysis (using a case fatality rate of 53%), with more individuals being ³⁸¹ overwhelmed and dying, or alternatively clearing the virus after around 12 days (Fig. [3\(b\)\)](#page-8-0). Despite $\frac{382}{100}$ these changes to the viral lifespan distribution, we observed similar viral dynamics. In particular, the 383 peak time of infection was unaffected as decreasing the fatality rate merely meant that the individual ³⁸⁴ trajectories were simulated for longer before they either dropped to the point where we considered the 385 individual no longer infected or the infected individual died. 386

Fig. 5. Posterior predictive distributions for URT viral titre metrics. (a) Posterior predictive distribution for V_U compared to the empirical data. We produced the posterior predictive distribution using the 1000 parameter samples from our inferred parameter posterior distribution in Fig. [4.](#page-13-0) We display the median (blue solid line), 95% pointwise prediction interval (shaded region) and the least-squares fit (dotted red line). Both the optimisation fit and ABC posterior show reasonable concordance to the main data trends. **(b)** As for **(a)**, but showing all posterior predictive trajectories as opposed to the distribution summary. **(c)** Posterior viral titre peak-time distribution showing that the majority of infections peak just before day five. This is consistent with the data, which shows a peak around day five to day six (post infection).

Fig. 6. Posterior predictions for $v, r(t)$ **. Both plots show the 1000 posterior trajectories, with** the blue lines representing H5N1 influenza patients who survive the infection (cleared the virus) and the red lines representing patients who died due to the infection (where the distinction is made using the method in Section [2.1.6\)](#page-7-0). **(a)** Virion count distribution found using the parameter posterior in Fig. [4.](#page-13-0) After day 6, the viral count trajectories for deceased patients are higher and more sustained than surviving patients. These were calculated from the one million BPM realisations each with an initial viral load of 10⁶ and a mutation chance of 10⁻⁵ per replication. **(b)** Distribution of $r(t)$ calculated from the posterior predictive distribution shown in Fig. [5\(a\).](#page-15-0) Surviving patients tended to have higher $r(t)$ during the second peak around day 7, which then declined below one (indicating a decreasing virion count) more rapidly than for dying patients. (c) Maximum r value vs viral lifespan. Maximum r values taken from Fig. $6(b)$ and corresponding viral lifespans are shown in Fig. [3.](#page-8-0) Blue circles represent H5N1 influenza patients who survive the infection (cleared the virus). Red circles represent patients who died due to the infection (where the distinction is made using the method in Section [2.1.6\)](#page-7-0). Surviving individuals tended to have shorter viral lifespans. Otherwise, there was no evident dependencies between maximum r value and the viral lifespan.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

3.3 Human-to-human transmission probabilities 387

With estimates for the viral lifespan distribution and effective replication number from the parameter 388 posterior distribution, we used our BPM to investigate viral mutation dynamics. Recall that we ³⁸⁹ performed two sets of BPM realisations: one set with one million BPM realisations (1000 copies of ³⁹⁰ the 1000 sample sets in the posterior parameter distribution) that each had an initial viral load of ³⁹¹ $10⁶$ virions; a second set with 1000 BPM realisations (one for each sample comprising our parameter $\frac{392}{2}$ posterior distribution) that each had an initial viral load of $10^6 \times 10^6$. **.** 393

From the first set of one million BPM realisations (see Section [2.3\)](#page-10-0) we calculated the proportion of ³⁹⁴ mutant strains over time (Fig. [7\(a\)\)](#page-18-0) and probability of having at least one virion with x mutations over $\frac{395}{2}$ time (Fig. [7\(b\)\)](#page-18-0). We found that virions with the required number of mutations for human-to-human $\frac{396}{2}$ transmission (three or more) made up a very small proportion of the viral load - around five orders of ³⁹⁷ magnitude less than the strain with the next smallest proportion. 398

The derived probability approximation (Section [2.3\)](#page-10-0) gave a generally sound upper bound, following ³⁹⁹ a similar shape as the exact probability. A couple of exceptions were when a mutation first occurred ⁴⁰⁰ and when the virus population died off near the end of the infection (Fig. [7\(b\)\)](#page-18-0). This reflected the $\frac{401}{401}$ dependence on the population of other mutants being more pronounced at lower numbers of virions ⁴⁰² (where the presence of a four mutation strain, for example, is almost purely from mutations from zero, ⁴⁰³ one, two, three strain virions). When a strain reaches 'persistence levels' within the total population, ⁴⁰⁴ the estimate as an upper bound is more robust as the majority of each strain comes from the replication 405 of said strain (and not via mutation). We note that the probability of at least one virion having the ⁴⁰⁶ required four out of four mutations is zero for almost all of the infections simulated, apart from the $_{407}$ time period between five and seven days where two out of the one million BPM realisations had at $\frac{408}{408}$ least one virion with these mutations before both strains died out. ⁴⁰⁹

The set of BPM realisations with a higher starting load (of $10^6 \times 10^6$ initial virions) allowed for a more 410 precise computation of the proportion of mutant virions (Fig. [7\(c\)\)](#page-18-0). Although some virions mutated $_{411}$ further along the pathway to droplet transmission (compared to the realisations with a lower initial $_{412}$ viral load), they only made up a very small proportion of the total virion count. Similarly, for the ⁴¹³ estimates of the probability of observing at least one mutant with the required number of mutations ⁴¹⁴ (Fig. [7\(d\)\)](#page-18-0), probabilities of obtaining either four or five required mutations for droplet transmission $\frac{415}{2}$ were very low across the entire infection duration. 416

In the case where we considered a lower case fatality rate of 20% (rather than a case fatality rate of $_{417}$ 53%), we observed similar mutation probabilities (Fig. [S3\)](#page-30-0). As expected, by lowering the case fatality ⁴¹⁸ rate the overall viral dynamics remained near identical for the majority of the infectious period. As $_{419}$ such, the mutation probabilities were not affected until the end of the infection, by which point the $\frac{420}{420}$ peak of the mutation probabilities had already occurred. ⁴²¹

Fig. 7. Mutated virion statistics with respect to time elapsed post infection, computed from BPM realisations. Line shading corresponds to the number of mutations (one mutation the lightest shading through to five mutations being the darkest shading). In all BPM simulations we fixed the probability of mutation at 10−⁵ per replication. In panels **(a&b)**, each realisation had an initial viral load of 10⁶. We ran 1000 realisations of each of the 1000 posterior parameter sets (Fig. [4\)](#page-13-0). In panels (c&d), each realisation had an initial viral load of $10^6 \times 10^6$. We ran one realisation of each of the 1000 posterior parameter sets (Fig. [4\)](#page-13-0). **(a,c)** Proportion of total virions with the specified amount of mutations. There were a very small proportion of virions that have the required number of mutations to achieve droplet transmission (three or more mutations). **(b,d)** Probability of having a mutation strain. We present the estimated probabilities as the dashed lines with circle markers. We present the actual probabilities as solid lines. Probability estimate derivation follows that given in Section [2.2.](#page-9-0) The estimated probabilities are a clear upper bound on the true probabilities. Depending on the number of mutations in the initial infecting virions, there was a low probability of achieving the required number of mutations near the beginning on the infection lifespan (which would allow more replication of the mutant strains).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

4 Discussion ⁴²²

This paper presents a novel two-patch within-host model for an H5N1 influenza infection in a human 423 host. Compared to existing literature, we explicitly model the lower and upper human respiratory 424 tracts; this formulation enables us to mechanistically model the different biological responses to the ⁴²⁵ infection in each tract. We also extend the earlier work of Russell *et al.* [\[6\]](#page-23-5) to allow for more realistic $\frac{426}{426}$ modelling of virus mutations within a host. With these modelling developments we explored the risk of $_{427}$ developing a human-to-human transmissible form of H5N1 influenza. Together these methods provide 428 a general framework for combining within-host infection and within-host mutation models, which may ⁴²⁹ be readily adapted to other (primarily respiratory) contagions. $\frac{430}{400}$

The fitted within-host model displayed a preference for H5N1 influenza to spread in the LRT compared 431 to the URT. This finding conforms with biological observations of a greater ease of spread for H5N1 ⁴³² influenza in the LRT (compared to the URT) $[7, 8]$ $[7, 8]$. Also evident was the multi-modal nature of $\frac{433}{4}$ URT parameter posteriors. This is likely due to the URT behaving like a target-cell-limited model, $_{434}$ in that the spread is only limited by the population of target-cells (as all of them become infected). ⁴³⁵ Contagion dynamics are therefore less sensitive to the parameter values in the URT, resulting in the ⁴³⁶ multi-modality of the parameter posterior distributions. Due to the higher target-cell numbers in ⁴³⁷ the LRT, once the virus reaches the LRT the dynamics are much more sensitive to these parameters $\frac{438}{438}$ (β_L, p_L) . As a consequence, the posterior has a much tighter peak around the mode. As previously 439 stated, the qualitative shape of the median posterior predictive trajectory for viral titres in the URT ⁴⁴⁰ is very similar to other models found in the literature [\[7,](#page-23-8) [14,](#page-24-3) [18,](#page-24-7) [36\]](#page-25-8).

The analysis of the relationship between maximum effective replication number/growth rate, and peak ⁴⁴² viral load and infection lifespan revealed no correlation between these two variables. For the majority ⁴⁴³ of infections, there was a second peak at around day eight corresponding to a delayed peak in the lower ⁴⁴⁴ respiratory tract, which previous studies have indicated are to be biologically expected [\[19\]](#page-24-8). Under our ⁴⁴⁵ default modelling assumptions all posterior predictive viral lifespans were less than 13.5 days. This is ⁴⁴⁶ in agreement with the scenarios presented in Russell *et al.* [\[6\]](#page-23-5), where they take the length of infection $\frac{447}{400}$ to be 10 days. $\frac{448}{2}$

The modifications we made to an existing BPM for viral mutation, namely incorporating time- ⁴⁴⁹ dependent replication rates and a realistic infectious duration distribution, gave comparable results ⁴⁵⁰ to Russell *et al.* [\[6\]](#page-23-5). As the upper bound on the probabilities (of having at least one virion with x_{451} mutations) were of extremely low orders of magnitude, it seems highly unlikely that a typical human ⁴⁵² infection would lead to the arrival of a strain with four or five mutations. There is a much higher 453 probability of having at least one virion with the (minimal) required three mutations, which may ⁴⁵⁴ indicate that, with a large enough outbreak, we would expect a human-transmissible strain to evolve ⁴⁵⁵ within at least one individual. Nonetheless, the proportion of virions with this strain is still expected $\frac{456}{456}$ to be very low and so transmission of such strains (even if present) is unlikely [\[6\]](#page-23-5). In contrast, strains ⁴⁵⁷ with one or two mutations were generally highly prevalent amongst the virion population. Outbreaks $\frac{458}{458}$ in mammals (in particular the large number of infections in the US dairy industry [\[37\]](#page-25-9)), whose respira- ⁴⁵⁹ tory tracts are more similar to humans than avian species, may mean that human secondary infections ⁴⁶⁰ from these animal cases are caused by a strain that is further along the mutation pathway to droplet ⁴⁶¹ transmissibility. Thus, there may be a higher than modelled risk of reaching the required number ⁴⁶² of mutations if a human is infected by a strain transmitted from other mammals, rather than birds. ⁴⁶³ Russell *et al.* [\[6\]](#page-23-5) considers differing initial mutations and also differing fitnesses of mutant strains. ⁴⁶⁴ They conclude that although this does increase the proportions and probabilities stated, they are ⁴⁶⁵ still sufficiently small such that these changes are unlikely to lead to a meaningful increase in the ⁴⁶⁶ probability of human-to-human transmission, with which we concur.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Our work has not considered the probability of virions in the respiratory tracts being present in ⁴⁶⁸ exhaled droplets and instead focused on the probability of mutating a droplet-transmissible variant. ⁴⁶⁹ Consequently, the probabilities present in this paper are not equivalent to the probability of any H5N1 $_{470}$ influenza infection in a human leading to a droplet transmissible virus. Nonetheless, our work does ⁴⁷¹ provide a framework for making this calculation. In the future, the development of a proxy or a further 472 calculation from the results presented is required to make a conclusion on this transmission probability. ⁴⁷³ In principle, any time that $p_t^{(i)} > 0$, there is a chance of human-to-human droplet transmission, with α higher proportions of mutant strains corresponding to a higher likelihood of droplet transmission, 475 though the exact relationship between these two entities is unclear. Our results show that it is unlikely, ⁴⁷⁶ albeit not impossible, that a human infection of H5N1 influenza could lead to onwards transmission of ⁴⁷⁷ a droplet transmissible strain. The probability results indicate that the presence of previous mutations $\frac{478}{478}$ at infection onset are more worrying than the development of the strain through mutations, as this ⁴⁷⁹ would provide more time for a droplet transmissible strain to reach persistence levels in a host. Droplet $_{480}$ transmissible strains mutating earlier in the infection pose a more significant threat as early mutations ⁴⁸¹ lead to higher proportions of mutant strains within the individual throughout the length of infection. $_{482}$ Furthermore, an early mutation is likely to correspond with a longer period in which an infected $\frac{483}{100}$ individual is symptomatic with said mutant strain, and this leads to a higher probability of this ⁴⁸⁴ mutant strain being droplet transmitted to another human. 485

The model we have presented is necessarily a simplified representation of reality. It is important that $_{486}$ we consider the modelling assumptions made and their potential limitations. Here we elaborate on the $_{487}$ implications of: the quality of the dataset used, estimation of the infection fatality ratio, estimation $\frac{488}{100}$ of the infection duration and initial viral load assumptions. ⁴⁸⁹

We note that there may be multiple issues with the data. Although our two-patch posterior predictions $\frac{490}{400}$ are very similar to other fitted models [\[7,](#page-23-8) [14,](#page-24-3) [18,](#page-24-7) [36\]](#page-25-8), all within-host models for H5N1 influenza spread $_{491}$ in human hosts that use this dataset suffer from a lack of parameter identifiability and biological ⁴⁹² certainty. In particular, due to the small size of the dataset, and because all individuals died (even ⁴⁹³ when given neuraminidase inhibitors), the average viral load may be much lower and viral lifespan 494 much longer than is shown in our model. That being said, at the time of writing this dataset is the ⁴⁹⁵ most recent and complete human infection data available for H5N1 influenza, providing an initial basis ⁴⁹⁶ for the exploration of the effects of our novel two-tract within-host infection model. 497

With regards to the estimation of the infection fatality ratio, at the time of writing, recorded cases $\frac{498}{4}$ are primarily hospitalisations and are therefore more likely to result in fatalities than unrecorded ⁴⁹⁹ infections. Indeed, individuals could have been infected with H5N1 influenza and exhibited seasonal $\frac{500}{200}$ flu-like symptoms, or been asymptomatic. More recent studies also estimate a larger seroprevalence $\frac{501}{200}$ of H5N1 influenza in humans than previously calculated, implying that the actual fatality rate of an ⁵⁰² H5N1 influenza infection is lower than previously thought [\[38](#page-25-10)[–40\]](#page-25-11). We assumed a default value for $\frac{503}{2}$ the infection fatality ratio of 53%, based on the reported case fatality ratio, which is therefore likely 504 to be an overestimate. Nonetheless, our sensitivity analysis with a lower infection fatality ratio gave \sim 505 similar qualitative conclusions. Further infection data for H5N1 influenza viral titres in humans would $\frac{1}{506}$ be required for more accurate modelling estimates and conclusions. It is important that new cases are $\frac{507}{200}$ thoroughly documented, such that future H5N1 influenza models have improved accuracy, especially sos at the beginning and end of the infection dynamics.

The third form of limitation relates to how pharmaceutical measures could impact the infectious ⁵¹⁰ duration of those infected with H5N1 influenza. Treatments, such as antivirals and neuraminidase $\frac{511}{200}$ inhibitors can reduce the viral load in individuals infected with H5N1 influenza exist and have been ⁵¹² shown to be effective [\[18,](#page-24-7) [41,](#page-25-12) [42\]](#page-26-0). If infection with H5N1 influenza was caught early on then hospitalised $\frac{1}{13}$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

individuals could be treated, with the resulting lower mortality rates and longer infection lengths ⁵¹⁴ plausibly leading to higher than estimated probabilities of obtaining a droplet transmissible strain ⁵¹⁵ (similar treatments for COVID-19 patients led to higher mutation chances [\[43\]](#page-26-1)). We note however, ⁵¹⁶ that in the dataset used, all individuals who presented with H5N1 influenza were subsequently given $\frac{517}{20}$ neuraminidase inhibitors, and yet all died due to their infection. Thus, it may be that in the majority 518 of individuals, such treatments do not produce any meaningful increase in duration of infection of ⁵¹⁹ H5N1 influenza in humans. ⁵²⁰

Lastly, we had to make an assumption about initial viral load (which we fixed as 1.3×10^3 TCID₅₀/ml). ϵ_{21} Given the infection data used is primarily centred around the peak of infection, our inference is most 522 strongly determined by this peak behaviour. As a consequence, the early growth rate corresponds to $\frac{523}{100}$ parameter estimates that give the 'correct' peak height and time for the data, given the assumed initial ⁵²⁴ viral load. A change in this viral load would change the growth rate with a negative correlation to the $=$ 525 initial viral load. Nonetheless, the viral lifespan distribution should be similar (as it is a function of the 526 peak time and area under the curve, which should not be affected much by the early rates of growth). ⁵²⁷ For the mutations model, a change in the initial viral load would result in the same proportions (as $\frac{528}{100}$ they are primarily dependent on the mutation probability) as shown in our results. However, the ⁵²⁹ curves for mutant strain *probabilities* would be shifted up and towards the left such that there are ⁵³⁰ increased probabilities of observing strains with higher numbers of mutations earlier in the infection. ⁵³¹

In addition to the aforementioned ideas for additional work, another direction for further investigations $\frac{532}{2}$ is the application of the model framework to infectious episodes in immunocompromised individuals. $\frac{1}{5}$ 533 During the COVID-19 epidemic, immunocompromised individuals were a large cause for concern for ⁵³⁴ the creation of new variants due to their longer duration of infection $[43-45]$. To our knowledge, there $\frac{535}{12}$ have been no reported cases of an immunocompromised individual being infected by H5N1 influenza, $\frac{536}{2}$ and thus it is unclear how they would respond to the infection. As previously stated, the main cause $\frac{537}{2}$ of death in those who contracted H5N1 influenza is currently believed to be cytokine storm. This ⁵³⁸ was also the leading cause of death from the Spanish flu epidemic in 1918-1920, but the fatality rate $\frac{539}{2}$ was lower for the immunocompromised as they did not exhibit a sufficient immune response to cause $\frac{540}{100}$ a cytokine storm [\[46,](#page-26-3) [47\]](#page-26-4). As a result, it may be that immunocompromised individuals are able to $\frac{541}{541}$ sustain longer periods of infection, thus giving a larger probability of a human-to-human transmissible ⁵⁴² strain mutating during their infection period. It is also possible that the virus simply overwhelms the ⁵⁴³ body of the immunocompromised, leading to rapid death, and thus little chance of producing mutant ⁵⁴⁴ strains of H5N1 influenza. Our current datasets are unable to distinguish between these possible ⁵⁴⁵ outcomes. The literature also shows that infections from H5N1 influenza can spread to other organs ⁵⁴⁶ and parts of the body [\[17\]](#page-24-6); it is likely that more detailed mortality modelling would need to take this $\frac{547}{547}$ into account with different mortality modelling methods for immunocompromised people.

In this paper we have provided a model framework that gives the basis for the calculation of the $\frac{549}{2}$ probability that the increased prevalence of influenza $A(H5N1)$ in both birds and mammals leads 550 to a human infection that develops the ability for droplet transmission. These advancements in ⁵⁵¹ modelling tools can help us determine how pandemic preparedness resources may be best focused ⁵⁵² between infection directly from avian hosts or from mammalian hosts. Indeed, our process is not just ⁵⁵³ relevant to H5N1 influenza, but also for any pathogen for which within-host mutations are a concern. ⁵⁵⁴

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Author contributions

DH, LJ, RS and MJK were supported by the Engineering and Physical Sciences Research Council $\frac{571}{20}$ through the MathSys CDT [grant number EP/S022244/1]. MJK was also supported by the Medical ⁵⁷² Research Council through the JUNIPER partnership award [grant number $MR/X018598/1$]. EMH $_{573}$ is also a member of the JUNIPER partnership (MRC grant no $MR/X018598/1$) and would like to 574 acknowledge their help and support. EMH is affiliated to the National Institute for Health and Care ⁵⁷⁵ Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University ⁵⁷⁶ of Liverpool (PB-PG-NIHR-200910), in partnership with the UK Health Security Agency (UKHSA), ⁵⁷⁷ in collaboration with the University of Warwick (EMH is based at The University of Liverpool). The $_{578}$ views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of $\frac{579}{20}$ Health and Social Care or the UK Health Security Agency. The research was funded by The Pandemic ⁵⁸⁰ Institute, formed of seven founding partners: The University of Liverpool, Liverpool School of Tropical ⁵⁸¹ Medicine, Liverpool John Moores University, Liverpool City Council, Liverpool City Region Combined ⁵⁸² Authority, Liverpool University Hospital Foundation Trust, and Knowledge Quarter Liverpool (EMH 583 is based at The University of Liverpool). The views expressed are those of the author(s) and not ⁵⁸⁴ necessarily those of The Pandemic Institute. The funders had no role in study design, data collection $\frac{1}{585}$ and analysis, decision to publish, or preparation of the manuscript. For the purpose of open access, $\frac{586}{100}$ the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted 587 Manuscript version arising from this submission. $\frac{1}{100}$ submission.

Data availability 589

All data utilised in this study are publicly available, with relevant references and data repositories $\frac{590}{2}$ $\boldsymbol{\mathrm{provided.}} \tag{59}$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Code availability 592

Competing interests

All authors declare that they have no competing interests.

References

- [1] World Health Organisation. The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention (2023). URL [https://www.who.int/publications/m/item/](https://www.who.int/publications/m/item/the-panzootic-spread-of-highly-pathogenic-avian-influenza-h5n1-sublineage-2.3.4.4b--a-critical-appraisal-of-one-health-preparedness-and-prevention) [the-panzootic-spread-of-highly-pathogenic-avian-influenza-h5n1-sublineage-2.](https://www.who.int/publications/m/item/the-panzootic-spread-of-highly-pathogenic-avian-influenza-h5n1-sublineage-2.3.4.4b--a-critical-appraisal-of-one-health-preparedness-and-prevention) [3.4.4b--a-critical-appraisal-of-one-health-preparedness-and-prevention](https://www.who.int/publications/m/item/the-panzootic-spread-of-highly-pathogenic-avian-influenza-h5n1-sublineage-2.3.4.4b--a-critical-appraisal-of-one-health-preparedness-and-prevention). [Online] (Accessed: 19 December 2024).
- [2] Centres for Disease Control and Prevention (CDC). Past Reported Global Human Cases with Highly Pathogenic Avian Influenza A(H5N1) (HPAI H5N1) by Country, 1997-2024 (2024). URL [https://www.cdc.gov/bird-flu/php/avian-flu-summary/](https://www.cdc.gov/bird-flu/php/avian-flu-summary/chart-epi-curve-ah5n1.html) [chart-epi-curve-ah5n1.html](https://www.cdc.gov/bird-flu/php/avian-flu-summary/chart-epi-curve-ah5n1.html). [Online] (Accessed: 19 December 2024).
- [3] Sah R, Mohanty A, Rohilla R, Mehta R, Leon-Figueroa DA, *et al.* Human death due to H5N1 amid the COVID-19 pandemic and mpox outbreak: A call for action. *Int J Surg* **109**(3):576–578 (2023).
- [4] World Health Organisation. Disease Outbreak News, Avian Influenza A(H5N1) - Vietnam (2024). URL <https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON511>. [Online] (Accessed: 19 December 2024).
- [5] Centres for Disease Control and Prevention (CDC). Clinical Signs and Symptoms of Influenza (2024). URL <https://www.cdc.gov/flu/professionals/acip/clinical.htm>. [Online] (Accessed: 19 December 2024).
- [6] Russell CA, Fonville JM, Brown AEX, Burke DF, Smith DL, *et al.* The Potential for Respiratory Droplet–Transmissible A/H5N1 Influenza Virus to Evolve in a Mammalian Host. *Science* **336**(6088):1541–1547 (2012). doi:10.1126/science.1222526.
- [7] Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, *et al.* Exploring Cell Tropism as a Possible Contributor to Influenza Infection Severity. *PLOS ONE* **5**(11):1–15 (2010). doi: 10.1371/journal.pone.0013811.
- [8] Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, De Wit E, *et al.* Airborne transmission of influenza A/H5N1 virus between ferrets. *science* **336**(6088):1534–1541 (2012).
- [9] Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, *et al.* Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. *Nature* **486**(7403):420–428 (2012).

- [10] Kuchipudi SV, Nelli RK, Gontu A, Satyakumar R, Surendran Nair M, *et al.* Sialic Acid Receptors: The Key to Solving the Enigma of Zoonotic Virus Spillover. *Viruses* **13**(2) (2021). doi:10.3390/ v13020262.
- [11] World Health Organisation. Respiratory Infections (2024). URL [https://platform.who.int/](https://platform.who.int/mortality/themes/theme-details/topics/topic-details/MDB/respiratory-infections) [mortality/themes/theme-details/topics/topic-details/MDB/respiratory-infections](https://platform.who.int/mortality/themes/theme-details/topics/topic-details/MDB/respiratory-infections). [Online] (Accessed: 19 December 2024).
- [12] Ait Mahiout L, Bessonov N, Kazmierczak B, Volpert V. Mathematical modeling of respiratory viral infection and applications to SARS-CoV-2 progression. *Math Methods Appl Sci* (2022).
- [13] Ciupe SM, Tuncer N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. *Sci Rep* **12**(1):14637 (2022).
- [14] Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. *PLOS Computational Biology* **16**(4):1–29 (2020). doi:10.1371/journal.pcbi.1007705.
- [15] Fonville JM, Burke DF, Lewis NS, Katzelnick LC, Russell CA. Quantifying the fitness advantage of polymerase substitutions in Influenza A/H7N9 viruses during adaptation to humans. *PLoS One* **8**(9):e76047 (2013).
- [16] Fonville JM. Expected Effect of Deleterious Mutations on Within-Host Adaptation of Pathogens. *Journal of Virology* **89**(18):9242–9251 (2015). doi:10.1128/jvi.00832-15.
- [17] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, *et al.* Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nature Medicine* **12**(10):1203–1207 (2006). doi:10.1038/nm1477.
- [18] Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. *Journal of Theoretical Biology* **269**(1):234–244 (2011). doi:https://doi.org/10.1016/j.jtbi.2010.10.017.
- [19] Handel A, Longini IM, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. *Journal of The Royal Society Interface* **7**(42):35–47 (2010). doi:10.1098/rsif.2009.0067.
- [20] Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. *J Immunol* **172**(5):2731–2738 (2004).
- [21] Perlman RL. Mouse models of human disease: An evolutionary perspective. *Evolution, Medicine, and Public Health* **2016**(1):170–176 (2016). doi:10.1093/emph/eow014.
- [22] Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. *Journal of Clinical Bioinformatics* **2**(1):5 (2012). doi:10.1186/2043-9113-2-5.
- [23] Ciupe SM, Tuncer N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. *Sci. Rep.* **12**(1):14637 (2022).
- [24] Bocharov G, Romanyukha A. Mathematical model of antiviral immune response III. Influenza A virus infection. *Journal of Theoretical Biology* **167**(4):323–360 (1994).
- [25] Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, *et al.* Modeling amantadine treatment of influenza a virus in vitro. *Journal of theoretical biology* **254**(2):439–451 (2008).
- [26] Handel A, Longini Jr IM, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. *Journal of the Royal Society Interface* **7**(42):35–47 (2010).

- [27] Minter A, Retkute R. Approximate Bayesian Computation for infectious disease modelling. *Epidemics* **29**:100368 (2019). doi:https://doi.org/10.1016/j.epidem.2019.100368.
- [28] Filippi S, Barnes CP, Cornebise J, Stumpf MP. On optimality of kernels for approximate Bayesian computation using sequential Monte Carlo. *Statistical applications in genetics and molecular biology* **12**(1):87–107 (2013).
- [29] Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP. Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. *Journal of the Royal Society Interface* **6**(31):187–202 (2009).
- [30] Kogure T, Suzuki T, Takahashi T, Miyamoto D, Hidari KI, *et al.* Human trachea primary epithelial cells express both sialyl (α^2-3) Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl (α2-6) Gal receptor for human influenza viruses. *Glycoconjugate journal* **23**:101–106 (2006).
- [31] Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, *et al.* Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. *Journal of virology* **80**(15):7469–7480 (2006).
- [32] Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus. *Journal of Virology* **80**(16):8060–8068 (2006). doi:10.1128/jvi.00384-06.
- [33] Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, *et al.* Proinflammatory cytokine responses induced by influenza a (H5N1) viruses in primary human alveolar and bronchial epithelial cells. *Respir Res* **6**(1):135 (2005).
- [34] Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cell Mol Immunol* **13**(1):3–10 (2015).
- [35] Van Wesenbeeck L, D'Haese D, Tolboom J, Meeuws H, Dwyer DE, *et al.* A downward trend of the ratio of influenza RNA copy number to infectious viral titer in hospitalized influenza A-Infected patients. *Open Forum Infect Dis* **2**(4):ofv166 (2015).
- [36] Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. *Journal of virology* **80**(15):7590–7599 (2006).
- [37] Centres for Disease Control and Prevention (CDC). Current H5N1 Bird Flu Situation in Dairy Cows (2024). URL <https://www.cdc.gov/bird-flu/situation-summary/mammals.html>. [Online] (Accessed: 19 December 2024).
- [38] Nasreen S, Khan SU, Luby SP, Gurley ES, Abedin J, *et al.* Highly pathogenic avian influenza A(H5N1) virus infection among workers at live bird markets, bangladesh, 2009-2010. *Emerg Infect Dis* **21**(4):629–637 (2015).
- [39] Chen X, Wang W, Wang Y, Lai S, Yang J, *et al.* Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. *BMC Medicine* **18**(1):377 (2020). doi:10.1186/s12916-020-01836-y.
- [40] Gomaa M, Moatasim Y, El Taweel A, Mahmoud SH, El Rifay AS, *et al.* We are underestimating, again, the true burden of H5N1 in humans. *BMJ Global Health* **8**(8) (2023). doi: 10.1136/bmjgh-2023-013146.
- [41] Smith JR. Oseltamivir in human avian influenza infection. *J Antimicrob Chemother* **65 Suppl 2**(Suppl 2):ii25–ii33 (2010).

- [42] Couch RB, Davis BR. Has Oseltamivir been shown to be Effective for Treatment of H5N1 Influenza? *The Journal of Infectious Diseases* **202**(8):1149–1151 (2010). doi:10.1086/656317.
- [43] Bansal N, Raturi M, Bansal Y. SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward. *Transfus Clin Biol* **29**(2):161–163 (2021).
- [44] Ko KKK, Yingtaweesittikul H, Tan TT, Wijaya L, Cao DY, *et al.* Emergence of SARS-CoV-2 spike mutations during prolonged infection in immunocompromised hosts. *Microbiol Spectr* **10**(3):e0079122 (2022).
- [45] Raglow Z, Surie D, Chappell JD, Zhu Y, Martin ET, *et al.* SARS-COV-2 shedding and evolution in patients who were immunocompromised during the Omicron period: A multicentre, prospective analysis. *The Lancet Microbe* **5**(3) (2024). doi:10.1016/s2666-5247(23)00336-1.
- [46] Liu Q, Zhou Yh, Yang Zq. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cellular & Molecular Immunology* **13**(1):3–10 (2016). doi:10.1038/ cmi.2015.74.
- [47] Woo G. Age-dependence of the 1918 pandemic. *British Actuarial Journal* **24**:e3 (2019). doi: 10.1017/S1357321719000023.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Supporting Information Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans

Daniel Higgins^{1,2‡*}, Joshua Looker^{1,2‡*}, Robert Sunnucks^{1,2‡*}, Jonathan Carruthers³, Thomas Finnie³, Matt J. Keeling^{2,4}, Edward M. Hill^{5,6*}

1 EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, United Kingdom.

2 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom.

3 Data, Analytics and Surveillance, UK Health Security Agency, London, United Kingdom. **4** Mathematics Institute and School of Life Sciences, University of Warwick, Coventry, United Kingdom.

5 Civic Health Innovation Labs and Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.

6 NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, United Kingdom.

‡These authors contributed equally to this work.

* Corresponding Authors. Emails: daniel.higgins@warwick.ac.uk; joshua.looker@warwick.ac.uk; rob.sunnucks@warwick.ac.uk; edward.hill@liverpool.ac.uk.

Table of Contents

[S1 Additional tables](#page-28-1) 2

[S2 Additional figures](#page-28-2) 2

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

S1 Additional tables

Table S1. List of least-squares fit parameters: and their descriptions. Parameters fitted to the data in the log-space using the 'scipy.optimize' library in Python.

Parameter		Value
β_U	Rate of infection, URT	3.027×10^{-7}
β_L	Rate of infection, LRT	9.59×10^{-4}
p_U	Virus production rate, URT	0.588
p_L	Virus production rate, LRT	7.71×10^{-2}
γ	Conversion between infectious virions and $TCID_{50}$ / PFU	1.16×10^{-2}
D	Rate of diffusion of free virions	0.215
\boldsymbol{a}	Rate of advection	1.95×10^{-2}

S2 Additional figures

Fig. S1. Posterior predictions for $v, r(t)$ assuming a lower case mortality rate $(20\%$ **instead of 53%).** Both plots show the 1000 posterior trajectories, with the blue lines representing H5N1 influenza patients who survive the infection (cleared the virus) and the red lines representing patients who died due to the infection (where the distinction is made using the method in Section [2.1.6\)](#page-7-0). **(a)** Virion count distribution found using the parameter posterior in Fig. [4.](#page-13-0) The viral count trajectories for deceased patients are lower and more sustained than surviving patients. We calculated these viral count trajectories from the one million BPM realisations each with an initial viral load of 10⁶ and a mutation chance of 10⁻⁵ per replication. **(b)** Distribution of $r(t)$ calculated from the posterior predictive distribution shown in Fig. [5\(a\).](#page-15-0) Surviving patients tended to have higher $r(t)$ in the second peak around day 7 on infection, which then declined below one (indicating a decreasing virion count) more rapidly than for dying patients.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.01.24312235;](https://doi.org/10.1101/2024.09.01.24312235) this version posted December 20, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

Fig. S2. Maximum r **value vs viral lifespan assuming a lower case mortality rate (20% instead of 53%).** We observe a strong negative correlation between maximum r value and the viral lifespan. Maximum r values taken from Fig. [6\(b\)](#page-16-0) and corresponding viral lifespans are shown in Fig. [3.](#page-8-0) Blue circles represent H5N1 influenza patients who survive the infection (cleared the virus). Red circles represent patients who died due to the infection (where the distinction is made using the method in Section [2.1.6\)](#page-7-0). Surviving individuals tended to have lower viral lifespans.

Fig. S3. Mutated virion statistics with respect to time elapsed post infection, computed from BPM realisations assuming a lower case mortality rate (20% instead of 53%). Line shading corresponds to the number of mutations (one mutation the lightest shading through to five mutations being the darkest shading). In all BPM simulations we fixed the probability of mutation at 10−⁵ per replication. In panels **(a&b)**, each realisation had an initial viral load of 10⁶ . We ran 1000 realisations of each of the 1000 posterior parameter sets (Fig. [4\)](#page-13-0). In panels **(c&d)**, each realisation had an initial viral load of $10^6 \times 10^6$. We ran one realisation of each of the 1000 posterior parameter sets (Fig. [4\)](#page-13-0). **(a,c)** Proportion of total virions with the specified amount of mutations. There were a very small proportion of virions that have the required number of mutations to achieve droplet transmission (three or more mutations). **(b,d)** Probability of having a mutation strain. We present the estimated probabilities as the dashed lines with circle markers. We present the actual probabilities as solid lines. Probability estimate derivation follows that given in Section [2.2.](#page-9-0) The estimated probabilities are a clear upper bound on the true probabilities. Depending on the number of mutations in the initial infecting virions, there was a low probability of achieving the required number of mutations near the beginning on the infection lifespan (which would allow more replication of the mutant strains).